

A major chromatin regulator determines resistance of t killing

Science

359, 770-775

DOI: [10.1126/science.aao1710](https://doi.org/10.1126/science.aao1710)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antigen Presentation Keeps Trending in Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3239-3241.	3.2	7
2	High-throughput genetic screens using CRISPR-Cas9 system. <i>Archives of Pharmacal Research</i> , 2018, 41, 875-884.	2.7	23
3	Chromatin regulation and immune escape. <i>Science</i> , 2018, 359, 745-746.	6.0	10
4	Clear cell carcinomas of the ovary and kidney: clarity through genomics. <i>Journal of Pathology</i> , 2018, 244, 550-564.	2.1	41
5	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <i>Annals of Oncology</i> , 2018, 29, 812-824.	0.6	73
6	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
7	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
8	Tumor mutational burden as predictive factor of response to immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S358-S361.	1.3	8
9	The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer. <i>RSC Advances</i> , 2018, 8, 33464-33472.	1.7	6
10	Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. <i>Journal of Experimental Medicine</i> , 2018, 215, 3115-3135.	4.2	29
11	Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance. <i>Scientific Reports</i> , 2018, 8, 17292.	1.6	17
12	Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. <i>Cell</i> , 2018, 175, 1958-1971.e15.	13.5	378
13	Cancer research in the era of immunogenomics. <i>ESMO Open</i> , 2018, 3, e000475.	2.0	14
14	Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research. <i>CRISPR Journal</i> , 2018, 1, 379-404.	1.4	17
15	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
16	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2018, 13, 611-619.	1.7	3
17	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018, 6, 1511-1523.	1.6	59
18	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. <i>Trends in Biochemical Sciences</i> , 2018, 43, 1014-1032.	3.7	151

#	ARTICLE	IF	CITATIONS
19	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
20	Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens. <i>Cell</i> , 2018, 175, 1141-1155.e16.	13.5	107
21	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	13.5	892
22	Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. <i>Current Oncology Reports</i> , 2018, 20, 86.	1.8	61
23	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. <i>Mammalian Genome</i> , 2018, 29, 866-878.	1.0	10
24	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018, 24, 1143-1150.	15.2	212
25	SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. <i>Molecular Cancer Research</i> , 2018, 16, 1819-1825.	1.5	32
26	PBRM1 bromodomains variably influence nucleosome interactions and cellular function. <i>Journal of Biological Chemistry</i> , 2018, 293, 13592-13603.	1.6	33
27	Epigenetic modifiers: activities in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 599-614.	1.9	68
28	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nature Medicine</i> , 2018, 24, 556-562.	15.2	372
29	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. <i>Annual Review of Biomedical Data Science</i> , 2018, 1, 1-27.	2.8	27
30	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. <i>Nature Medicine</i> , 2018, 24, 1550-1558.	15.2	2,791
31	Pan-cancer deconvolution of tumour composition using DNA methylation. <i>Nature Communications</i> , 2018, 9, 3220.	5.8	205
32	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
33	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
34	Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. <i>Npj Genomic Medicine</i> , 2018, 3, 14.	1.7	33
35	DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade. <i>Developmental Cell</i> , 2019, 50, 658-671.e7.	3.1	76
36	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 5482-5489.	0.4	86

#	ARTICLE	IF	CITATIONS
37	Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.	1.7	35
38	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. <i>Cell</i> , 2019, 178, 585-599.e15.	13.5	162
39	Importance of genetic screens in precision oncology. <i>ESMO Open</i> , 2019, 4, e000505.	2.0	10
40	Determinants of immunological evasion and immuncheckpoint inhibition response in non-small cell lung cancer: the genetic front. <i>Oncogene</i> , 2019, 38, 5921-5932.	2.6	27
41	Poly Combs the Immune System: PRC2 Loss in Malignant Peripheral Nerve Sheath Tumors Can Dampen Immune Responses. <i>Cancer Research</i> , 2019, 79, 3172-3173.	0.4	0
42	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. <i>Nature Medicine</i> , 2019, 25, 1073-1081.	15.2	125
43	ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. <i>Cells</i> , 2019, 8, 678.	1.8	73
44	An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 166-177.	2.0	17
45	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	2.9	74
46	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 36, 597-612.e8.	7.7	100
48	Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1. <i>Cell Reports</i> , 2019, 29, 1645-1659.e9.	2.9	22
49	Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report. <i>Thoracic Cancer</i> , 2019, 10, 2312-2315.	0.8	66
50	Enhancer Dysfunction in 3D Genome and Disease. <i>Cells</i> , 2019, 8, 1281.	1.8	15
51	Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden. <i>Lung Cancer</i> , 2019, 138, 35-42.	0.9	53
52	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. <i>Cell Reports</i> , 2019, 28, 2784-2794.e5.	2.9	77
53	Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1349-1357.	7.7	226
54	Have Cells Harboring the HIV Reservoir Been Immunoedited?. <i>Frontiers in Immunology</i> , 2019, 10, 1842.	2.2	17
55	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019, 36, 385-401.e8.	7.7	359

#	ARTICLE	IF	CITATIONS
56	Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 247-256.	2.3	55
57	OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy. <i>Journal of Leukocyte Biology</i> , 2019, 105, 915-933.	1.5	22
58	CRISPR-Based Tools in Immunity. <i>Annual Review of Immunology</i> , 2019, 37, 571-597.	9.5	38
59	Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. <i>Genes and Development</i> , 2019, 33, 936-959.	2.7	127
60	Analysis of the transcriptomic features of microsatellite instability subtype colon cancer. <i>BMC Cancer</i> , 2019, 19, 605.	1.1	10
61	Î²-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
62	Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion. <i>Cancer Research</i> , 2019, 79, 3903-3915.	0.4	68
63	Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. <i>Annals of Oncology</i> , 2019, 30, 1401-1403.	0.6	72
64	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
65	EZH2 Regulates Protein Stability via Recruiting USP7 to Mediate Neuronal Gene Expression in Cancer Cells. <i>Frontiers in Genetics</i> , 2019, 10, 422.	1.1	31
66	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
67	Pharmacological Modulation of Transcriptional Coregulators in Cancer. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 388-402.	4.0	9
68	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 517-529.	1.5	15
69	PBRM1 Regulates Stress Response in Epithelial Cells. <i>IScience</i> , 2019, 15, 196-210.	1.9	24
70	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
71	Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 375-391.	1.1	30
72	TISIDB: an integrated repository portal for tumor-immune system interactions. <i>Bioinformatics</i> , 2019, 35, 4200-4202.	1.8	1,281
73	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. <i>Liver International</i> , 2019, 39, 43-62.	1.9	54

#	ARTICLE	IF	CITATIONS
74	Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 857-866.	0.5	27
75	Patient with anomalous skin pigmentation expands the phenotype of <i>ARID2</i> loss-of-function disorder, a SWI/SNF-related intellectual disability. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 808-812.	0.7	13
76	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
77	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 4592-4602.	3.2	447
78	Large-scale compound screens and pharmacogenomic interactions in cancer. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 12-16.	1.5	6
79	Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo. <i>Cell Systems</i> , 2019, 8, 136-151.e7.	2.9	14
80	Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report. <i>Thoracic Cancer</i> , 2019, 10, 1285-1288.	0.8	58
81	Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. <i>Genome Medicine</i> , 2019, 11, 18.	3.6	36
82	From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 33-40.	1.5	20
83	Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents. <i>EMBO Reports</i> , 2019, 20, .	2.0	31
84	Functional-genetic approaches to understanding drug response and resistance. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 41-47.	1.5	3
85	The prognostic landscape of interactive biological processes presents treatment responses in cancer. <i>EBioMedicine</i> , 2019, 41, 120-133.	2.7	6
86	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response. <i>PLoS ONE</i> , 2019, 14, e0210891.	1.1	13
87	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
88	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	15.2	569
89	SLFN11 can sensitize tumor cells towards IFN- γ -mediated T cell killing. <i>PLoS ONE</i> , 2019, 14, e0212053.	1.1	33
90	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
91	When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 36, 575-576.	7.7	10

#	ARTICLE	IF	CITATIONS
92	High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1. <i>Molecular Oncology</i> , 2019, 13, 811-828.	2.1	22
93	Predictors of disease aggressiveness influence outcome from immunotherapy treatment in renal clear cell carcinoma. <i>Oncolimmunology</i> , 2019, 8, e1500106.	2.1	18
94	Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degradable Probe of BRD9 and BRD7. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 699-726.	2.9	230
95	Cancer Neoantigens. <i>Annual Review of Immunology</i> , 2019, 37, 173-200.	9.5	384
96	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- κ B Activation and PD-L1 Expression. <i>Molecular Cell</i> , 2019, 73, 22-35.e6.	4.5	174
97	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
98	Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment. <i>Clinical Genetics</i> , 2020, 97, 73-88.	1.0	37
99	CRISPR technology for immuno-oncology applications. <i>Methods in Enzymology</i> , 2020, 635, 251-266.	0.4	1
100	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. <i>Seminars in Cancer Biology</i> , 2020, 61, 180-198.	4.3	28
101	Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 290-300.	3.2	142
102	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	10.6	856
103	Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 7.e1-7.e8.	0.8	8
104	MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2. <i>Biomedicine and Pharmacotherapy</i> , 2020, 122, 109696.	2.5	62
105	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 785-796.	0.6	18
106	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
107	In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2020, 10, 270-287.	7.7	129
108	The ART of Epigenetics in Melanoma: From histone Alterations, to Resistance and Therapies. <i>Theranostics</i> , 2020, 10, 1777-1797.	4.6	44
109	Heat-Triggered Remote Control of CRISPR-dCas9 for Tunable Transcriptional Modulation. <i>ACS Chemical Biology</i> , 2020, 15, 533-542.	1.6	23

#	ARTICLE	IF	CITATIONS
110	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3441-3452.	2.4	22
111	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
112	CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 583-587.	2.8	32
113	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
114	Methods and resources to access mutation-dependent effects on cancer drug treatment. <i>Briefings in Bioinformatics</i> , 2020, 21, 1886-1903.	3.2	5
115	Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 16.	1.7	72
116	Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. <i>Science Immunology</i> , 2020, 5, .	5.6	287
117	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
118	Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. <i>Trends in Genetics</i> , 2020, 36, 936-950.	2.9	172
119	BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy. <i>Cell Reports</i> , 2020, 32, 108073.	2.9	30
120	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
121	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
122	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	77
123	Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF- β 2 Signaling. <i>Cell Reports</i> , 2020, 31, 107570.	2.9	24
124	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
125	The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. <i>PLoS ONE</i> , 2020, 15, e0235705.	1.1	44
126	Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3300.	1.7	6
127	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. <i>Seminars in Cancer Biology</i> , 2022, 83, 57-76.	4.3	33

#	ARTICLE	IF	CITATIONS
128	Regulation of PD-L1 Expression by NF- κ B in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 584626.	2.2	179
129	Integrated molecular drivers coordinate biological and clinical states in melanoma. <i>Nature Genetics</i> , 2020, 52, 1373-1383.	9.4	36
130	PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes. <i>Science Advances</i> , 2020, 6, .	4.7	8
131	Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. <i>Nature</i> , 2020, 588, 693-698.	13.7	218
132	Targeting NF- κ B-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8470.	1.8	82
133	Recent Advances of Cell Membrane-Coated Nanomaterials for Biomedical Applications. <i>Advanced Functional Materials</i> , 2020, 30, 2003559.	7.8	122
134	Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome. <i>Biomarker Research</i> , 2020, 8, 26.	2.8	3
135	Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies. <i>Frontiers in Oncology</i> , 2020, 10, 1254.	1.3	45
136	Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5990-6002.	3.2	28
137	A Flexible, Pooled CRISPR Library for Drug Development Screens. <i>CRISPR Journal</i> , 2020, 3, 211-222.	1.4	7
138	Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2020, 6, 1405.	3.4	157
139	ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20159-20170.	3.3	329
140	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020, 10, 1061.	1.8	59
141	Mechanisms of Cancer Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1290.	1.3	159
142	PROTACs: New method to degrade transcription regulating proteins. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112698.	2.6	32
143	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
144	Germline genomes have a dominant heritable contribution to cancer immune evasion and immunotherapy response. <i>Quantitative Biology</i> , 2020, 8, 216-227.	0.3	2
145	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. <i>Genome Biology</i> , 2020, 21, 263.	3.8	15

#	ARTICLE	IF	CITATIONS
146	Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. <i>Genome Medicine</i> , 2020, 12, 90.	3.6	29
147	BAP1: Not just a BRCA1-associated protein. <i>Cancer Treatment Reviews</i> , 2020, 90, 102091.	3.4	89
148	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. <i>Biomarker Research</i> , 2020, 8, 34.	2.8	266
149	CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1912-1933.	7.7	71
150	Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1147-1158.	1.5	4
151	ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. <i>Nature Chemical Biology</i> , 2020, 16, 1208-1217.	3.9	53
152	ARID2 Chromatin Remodeler in Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 2152.	1.8	12
153	Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. <i>Nature</i> , 2020, 586, 120-126.	13.7	249
154	Targeting TANK-binding kinase 1 (TBK1) in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1065-1078.	1.5	26
155	Epigenomic Reprogramming as a Driver of Malignant Glioma. <i>Cancer Cell</i> , 2020, 38, 647-660.	7.7	66
156	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 127-143.	4.3	59
157	CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. <i>Cancer Cell International</i> , 2020, 20, 456.	1.8	7
158	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
159	Rho-associated protein kinase-dependent moesin phosphorylation is required for PD-L1 stabilization in breast cancer. <i>Molecular Oncology</i> , 2020, 14, 2701-2712.	2.1	24
160	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	5.8	46
161	The chromatin remodeler <sc>SRCAP</sc> promotes self-renewal of intestinal stem cells. <i>EMBO Journal</i> , 2020, 39, e103786.	3.5	10
162	Koebner phenomenon of vitiligo associated with Coffin-Siris syndrome. <i>European Journal of Dermatology</i> , 2020, 30, 310-311.	0.3	3
163	Discovery and Validation of a Metastasis-Related Prognostic and Diagnostic Biomarker for Melanoma Based on Single Cell and Gene Expression Datasets. <i>Frontiers in Oncology</i> , 2020, 10, 585980.	1.3	17

#	ARTICLE	IF	CITATIONS
164	Autophagy protects tumors from T cell-mediated cytotoxicity via inhibition of TNF-induced apoptosis. <i>Science Immunology</i> , 2020, 5, .	5.6	63
165	Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 608300.	1.3	6
166	A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma. , 2020, 8, e001866.		13
167	<p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12301-12316.	1.0	22
168	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020, 11, 2135.	5.8	114
169	Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing. <i>ACS Chemical Biology</i> , 2020, 15, 1685-1696.	1.6	13
170	Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID. <i>SLAS Discovery</i> , 2020, 25, 581-590.	1.4	6
171	In situ conversion of defective Treg into SuperTreg cells to treat advanced IPEX-like disorders in mice. <i>Nature Communications</i> , 2020, 11, 2781.	5.8	7
172	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
173	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. <i>Clinical Cancer Research</i> , 2020, 26, 4723-4736.	3.2	23
174	CRISPR screen in mechanism and target discovery for cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188378.	3.3	25
175	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23
176	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1140-1157.	7.7	97
177	Rational Cancer Treatment Combinations: An Urgent Clinical Need. <i>Molecular Cell</i> , 2020, 78, 1002-1018.	4.5	95
178	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 293-303.	0.8	25
179	NF- κ B and Its Role in Checkpoint Control. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3949.	1.8	45
180	How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy. <i>Cancer Research</i> , 2020, 80, 4037-4041.	0.4	25
181	Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4071.	1.8	23

#	ARTICLE	IF	CITATIONS
182	The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review. <i>Cell Proliferation</i> , 2020, 53, e12791.	2.4	23
183	Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. <i>Nature Communications</i> , 2020, 11, 1335.	5.8	75
184	Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. <i>Oncoimmunology</i> , 2020, 9, 1734268.	2.1	24
185	Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN- γ . <i>Nature Cancer</i> , 2020, 1, 291-301.	5.7	89
186	Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 769-780.	1.6	72
187	ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, e000438.		117
188	Synthetic immunity by remote control. <i>Theranostics</i> , 2020, 10, 3652-3667.	4.6	17
190	A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1206-1214.	1.6	9
191	Genetic Screening for Novel Regulators of Immune Checkpoint Molecules. <i>Trends in Immunology</i> , 2020, 41, 692-705.	2.9	2
192	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 580-592.	3.8	166
193	BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 30.	3.5	22
194	Improving Cancer Immunotherapy with CRISPR-Based Technology. <i>Advanced Biology</i> , 2020, 4, e1900253.	3.0	6
195	Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4770-4780.	3.3	76
196	Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100. <i>Cancer Science</i> , 2020, 111, 1324-1332.	1.7	27
197	Large-scale public data reuse to model immunotherapy response and resistance. <i>Genome Medicine</i> , 2020, 12, 21.	3.6	514
198	Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2020, 26, 193-199.	15.2	211
199	Tumor heterogeneity and clonal cooperation influence the immune selection of IFN- γ -signaling mutant cancer cells. <i>Nature Communications</i> , 2020, 11, 602.	5.8	81
200	Cancer immunotherapy: Pros, cons and beyond. <i>Biomedicine and Pharmacotherapy</i> , 2020, 124, 109821.	2.5	337

#	ARTICLE	IF	CITATIONS
201	Pooled InÂVtro and InÂVivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. <i>Cell Stem Cell</i> , 2020, 26, 782-792.e7.	5.2	131
202	Tumor Milieu Controlled by RB Tumor Suppressor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2450.	1.8	17
203	High-throughput synthetic rescue for exhaustive characterization of suppressor mutations in human genes. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 4209-4222.	2.4	2
204	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 37, 443-455.	7.7	444
205	Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. <i>Nature Biomedical Engineering</i> , 2020, 4, 531-543.	11.6	141
206	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients. , 2020, 8, e000447.		35
207	Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. <i>Clinical Cancer Research</i> , 2020, 26, 3901-3907.	3.2	72
208	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47
209	Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1189-1201.	1.5	14
210	The SWI/SNF complex in cancer â€” biology, biomarkers and therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 435-448.	12.5	297
211	Invited Review: Dysregulation of chromatin remodellers in paediatric brain tumours â€” SMARCB1 and beyond. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 57-72.	1.8	10
212	Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 2882-2890.	3.2	27
213	Small-Cell Carcinoma of the Ovary, Hypercalcemic Typeâ€”Genetics, New Treatment Targets, and Current Management Guidelines. <i>Clinical Cancer Research</i> , 2020, 26, 3908-3917.	3.2	82
214	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	0.6	134
215	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
217	Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. <i>Cancer Discovery</i> , 2021, 11, 736-753.	7.7	73
218	Immune responses in genomically simple SWI/SNFâ€”deficient cancers. <i>Cancer</i> , 2021, 127, 172-180.	2.0	7
219	Predicting immunotherapy response through genomics. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 1-9.	1.5	12

#	ARTICLE	IF	CITATIONS
220	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	9.6	956
221	Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. <i>Oncogene</i> , 2021, 40, 863-874.	2.6	25
222	Dissecting the immunogenomic biology of cancer for biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 133-134.	12.5	7
223	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1564-1572.e4.	0.3	20
224	SMARCA4 mutations in KRAS mutant lung adenocarcinoma: a multi-cohort analysis. <i>Molecular Oncology</i> , 2021, 15, 462-472.	2.1	29
225	Biology of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 29-56.	0.9	40
226	A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. <i>Nature Reviews Immunology</i> , 2021, 21, 116-128.	10.6	139
227	Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
228	Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. <i>Nature Medicine</i> , 2021, 27, 289-300.	15.2	64
229	Epigenetic modulation of immunotherapy and implications in head and neck cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 141-152.	2.7	21
230	Rapid advancement in cancer genomic big data in the pursuit of precision oncology. <i>Medical Journal of Indonesia</i> , 2021, 30, .	0.2	0
231	Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 629-639.	1.1	0
232	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. <i>Nature Cancer</i> , 2021, 2, 189-200.	5.7	36
233	Estrogen receptor beta signaling in CD8 ⁺ T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch. , 2021, 9, e001932.		17
234	Genome editing of immune cells using CRISPR/Cas9. <i>BMB Reports</i> , 2021, 54, 59-69.	1.1	8
235	The role of small molecules in cell and gene therapy. <i>RSC Medicinal Chemistry</i> , 2021, 12, 330-352.	1.7	3
236	MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	63
237	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. <i>Oncogenesis</i> , 2021, 10, 3.	2.1	25

#	ARTICLE	IF	CITATIONS
238	Integrin $\alpha 6 \beta 4$ TGF $\beta 2$ SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , 2021, 39, 54-67.e9.	7.7	99
239	Mutations in the IFN γ -JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. <i>Clinical Cancer Research</i> , 2021, 27, 3432-3442.	3.2	40
240	Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. <i>Nature Communications</i> , 2021, 12, 757.	5.8	55
241	Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. , 2021, 9, e001819.		19
242	Simultaneous Inhibition of LSD1 and TGF $\beta 2$ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment. <i>Cancer Discovery</i> , 2021, 11, 1970-1981.	7.7	39
243	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. <i>Nature Genetics</i> , 2021, 53, 332-341.	9.4	112
244	LUBAC-mediated linear ubiquitination: a crucial regulator of immune signaling. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2021, 97, 120-133.	1.6	18
245	ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer. <i>Oncogene</i> , 2021, 40, 2923-2935.	2.6	22
246	Systematic characterization of mutations altering protein degradation in human cancers. <i>Molecular Cell</i> , 2021, 81, 1292-1308.e11.	4.5	36
247	In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. <i>Cell</i> , 2021, 184, 1262-1280.e22.	13.5	107
248	An expanded universe of cancer targets. <i>Cell</i> , 2021, 184, 1142-1155.	13.5	135
249	Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. <i>Frontiers in Immunology</i> , 2021, 12, 636568.	2.2	394
250	Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors. <i>Physiology</i> , 2021, 36, 73-83.	1.6	29
251	In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. <i>Immunity</i> , 2021, 54, 571-585.e6.	6.6	50
252	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 653358.	2.2	19
253	Renal cell carcinoma pathology in 2021: a new need for renal cancer immune profiling™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	0.9	5
254	Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 3990-4002.	3.2	13
255	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. <i>Cancer Cell</i> , 2021, 39, 480-493.e6.	7.7	71

#	ARTICLE	IF	CITATIONS
256	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021, 11, 874-899.	7.7	107
257	The mitochondrial Ca ²⁺ uptake regulator, MICU1, is involved in cold stress-induced ferroptosis. <i>EMBO Reports</i> , 2021, 22, e51532.	2.0	41
258	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
259	Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study. <i>Case Reports in Oncology</i> , 2021, 14, 706-715.	0.3	15
260	PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance. <i>Current Cancer Drug Targets</i> , 2021, 21, 306-325.	0.8	4
261	CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 674467.	1.8	22
262	clAP1/2 antagonism eliminates MHC class II-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	25
263	Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. <i>Immunotherapy</i> , 2021, 13, 587-603.	1.0	13
264	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13583.	1.7	15
265	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
266	Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. <i>Molecules and Cells</i> , 2021, 44, 363-373.	1.0	13
267	Interrogating immune cells and cancer with CRISPR-Cas9. <i>Trends in Immunology</i> , 2021, 42, 432-446.	2.9	13
268	BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 659392.	1.8	18
269	MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. <i>Oncogene</i> , 2021, 40, 4930-4940.	2.6	41
270	Exploring liver cancer biology through functional genetic screens. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 690-704.	8.2	31
271	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6741.	1.8	28
272	Applying CRISPR Screen in Diabetes Research. <i>Diabetes</i> , 2021, 70, 1962-1969.	0.3	2
273	Expression of PD-L1 in EBV-associated malignancies. <i>International Immunopharmacology</i> , 2021, 95, 107553.	1.7	16

#	ARTICLE	IF	CITATIONS
275	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. <i>Cancer Research</i> , 2021, 81, 2888-2902.	0.4	66
276	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. <i>Cancer Cell</i> , 2021, 39, 845-865.e7.	7.7	503
277	Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. <i>Cell Metabolism</i> , 2021, 33, 1221-1233.e11.	7.2	138
278	A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18â€“SSX Induces Canonical BAF Destruction. <i>Cancer Discovery</i> , 2021, 11, 2620-2637.	7.7	26
279	The future of immune checkpoint combinations with tumor-targeted small molecule drugs. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 675-680.	1.1	2
280	Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7518.	1.8	17
281	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
282	Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma. <i>Medicine (United States)</i> , 2021, 100, e26650.	0.4	5
284	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. <i>Journal of the National Cancer Center</i> , 2021, 1, 75-87.	3.0	20
285	SMARCA4 and Other SWItch/Sucose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	0.5	49
286	The BAF chromatin remodeling complexes: structure, function, and synthetic lethality. <i>Biochemical Society Transactions</i> , 2021, 49, 1489-1503.	1.6	13
287	Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 6543-6558.	3.2	5
288	Epigenetic Regulation in Melanoma: Facts and Hopes. <i>Cells</i> , 2021, 10, 2048.	1.8	20
289	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
290	Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells. <i>Molecular Oncology</i> , 2022, 16, 148-165.	2.1	14
291	Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect. <i>Cancers</i> , 2021, 13, 3948.	1.7	9
292	Bioinformatic Analysis of Prognostic and Immune-Related Genes in Pancreatic Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-23.	0.7	2
293	Epigenomic links from metabolismâ€“methionine and chromatin architecture. <i>Current Opinion in Chemical Biology</i> , 2021, 63, 11-18.	2.8	5

#	ARTICLE	IF	CITATIONS
294	Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus. <i>American Journal of Human Genetics</i> , 2021, 108, 1590-1610.	2.6	9
295	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	29
296	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. <i>Journal of Cellular Physiology</i> , 2022, 237, 346-372.	2.0	13
297	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. <i>Life</i> , 2021, 11, 1029.	1.1	8
298	A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2238-2249.e12.	0.3	7
299	InÂvivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. <i>Cell</i> , 2021, 184, 5357-5374.e22.	13.5	79
300	Development and validation of a <i>PBRM1</i>-associated immune prognostic model for clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 6590-6609.	1.3	6
301	Mapping genomic and epigenomic evolution in cancer ecosystems. <i>Science</i> , 2021, 373, 1474-1479.	6.0	38
302	The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. <i>Science</i> , 2021, 373, 1327-1335.	6.0	83
303	PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. <i>Cancer Cell</i> , 2021, 39, 1214-1226.e10.	7.7	72
304	HOIP limits anti-tumor immunity by protecting against combined TNF and IFNÎ³-induced apoptosis. <i>EMBO Reports</i> , 2021, 22, e53391.	2.0	21
305	Identification of rare, transient post-mitotic cell states that are induced by injury and required for whole-body regeneration in <i>Schmidtea mediterranea</i> . <i>Nature Cell Biology</i> , 2021, 23, 939-952.	4.6	38
306	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
307	Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
308	Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. <i>Journal of Oncology</i> , 2021, 2021, 1-20.	0.6	26
309	Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy. <i>Methods in Molecular Biology</i> , 2020, 2115, 419-433.	0.4	8
310	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 143-166.	0.8	3
311	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	1.9	162

#	ARTICLE	IF	CITATIONS
326	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 599-613.	7.7	90
327	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. <i>Journal of Clinical Investigation</i> , 2019, 129, 3324-3338.	3.9	209
328	Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. <i>Journal of Clinical Investigation</i> , 2019, 129, 4224-4238.	3.9	95
329	Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2019, 129, 4316-4331.	3.9	143
330	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2712-2726.	3.9	112
331	Predictors of immunotherapy benefit in Merkel cell carcinoma. <i>Oncotarget</i> , 2020, 11, 4401-4410.	0.8	5
332	https://cdrjournal.com/article/view/3531 . , 2020, 3, 454-471.		4
333	Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. <i>ELife</i> , 2018, 7, .	2.8	25
334	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. <i>ELife</i> , 2019, 8, .	2.8	69
335	BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. <i>Nucleic Acids Research</i> , 2021, 49, 12211-12233.	6.5	29
337	The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?. <i>Frontiers in Oncology</i> , 2021, 11, 745187.	1.3	33
338	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. <i>Nature</i> , 2021, 598, 682-687.	13.7	117
339	RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 1018-1038.	5.7	11
340	Biochemistry, Pathophysiology, and Regulation of Linear Ubiquitination: Intricate Regulation by Coordinated Functions of the Associated Ligase and Deubiquitinase. <i>Cells</i> , 2021, 10, 2706.	1.8	13
341	The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 145-148.	0.9	20
342	PBRM1 Regulates the Stress Response in Epithelial Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
348	The CRISPR System and Cancer Immunotherapy Biomarkers. <i>Methods in Molecular Biology</i> , 2020, 2055, 301-322.	0.4	2
355	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. <i>Immuno-Oncology Technology</i> , 2021, 11, 100043.	0.2	9

#	ARTICLE	IF	CITATIONS
359	<i>In vivo</i> CRISPR Screens Identify E3 Ligase <i>Cop1</i> as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target. SSRN Electronic Journal, 0, .	0.4	0
360	Unleashing TNF cytotoxicity to enhance cancer immunotherapy. Trends in Immunology, 2021, 42, 1128-1142.	2.9	28
361	miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Biomolecules, 2021, 11, 1648.	1.8	15
362	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature Medicine, 2021, 27, 1910-1920.	15.2	62
363	Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?. European Urology, 2022, 81, 149-150.	0.9	3
364	Multifunctional Biomedical Materials Derived from Biological Membranes. Advanced Materials, 2022, 34, e2107406.	11.1	26
366	<i>MLL2</i> maintains <i>PD-L1</i> expression and mediates tumor immune resistance. EMBO Reports, 2020, 21, e50155.	2.0	13
367	CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients. Aging, 2020, 12, 21809-21836.	1.4	12
369	Identification and validation of significant gene mutations to predict clinical benefit of immune checkpoint inhibitors in lung adenocarcinoma. American Journal of Translational Research (discontinued), 2021, 13, 1051-1063.	0.0	1
370	CRISPR screen in cancer: status quo and future perspectives. American Journal of Cancer Research, 2021, 11, 1031-1050.	1.4	4
371	The Growing Relevance of Immunoregulation in Pediatric Brain Tumors. Cancers, 2021, 13, 5601.	1.7	7
372	Bridging Radiotherapy to Immunotherapy: The IFN γ -JAK-STAT Axis. International Journal of Molecular Sciences, 2021, 22, 12295.	1.8	13
373	Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma. Laboratory Investigation, 2022, 102, 352-362.	1.7	10
374	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 5981.	1.7	31
375	Tumor evolution selectively inactivates the core microRNA machinery for immune evasion. Nature Communications, 2021, 12, 7003.	5.8	7
376	Targeting cancer metabolism in the era of precision oncology. Nature Reviews Drug Discovery, 2022, 21, 141-162.	21.5	385
377	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. Cancers, 2021, 13, 6052.	1.7	15
378	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e15-166.e25.	0.8	6

#	ARTICLE	IF	CITATIONS
379	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. <i>Nature Communications</i> , 2022, 13, 42.	5.8	27
380	Spotlight on TAP and its vital role in antigen presentation and cross-presentation. <i>Molecular Immunology</i> , 2022, 142, 105-119.	1.0	31
381	How CRISPR/Cas9 Gene Editing Is Revolutionizing T Cell Research. <i>DNA and Cell Biology</i> , 2022, 41, 53-57.	0.9	1
382	High-throughput methods for genome editing: the more the better. <i>Plant Physiology</i> , 2022, 188, 1731-1745.	2.3	10
384	Current trends of functionalized nanomaterial-based sensors in point-of-care diagnosis. , 2022, , 337-353.		2
385	Multimic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	7.7	64
386	PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner. <i>Cancer Immunology Research</i> , 2022, 10, 285-290.	1.6	13
387	Novel Mouse Models for Cancer Immunology. <i>Annual Review of Cancer Biology</i> , 2022, 6, 269-291.	2.3	9
388	PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers. <i>Biomedicines</i> , 2022, 10, 299.	1.4	3
389	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. <i>Oncotmunology</i> , 2022, 11, 2029298.	2.1	17
390	Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.	12.8	101
391	Transcriptional determinants of cancer immunotherapy response and resistance. <i>Trends in Cancer</i> , 2022, 8, 404-415.	3.8	9
392	Extracellular matrix modulates T cell clearance of malignant cells in vitro. <i>Biomaterials</i> , 2022, 282, 121378.	5.7	8
393	HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. <i>Theranostics</i> , 2022, 12, 2080-2094.	4.6	17
394	High-content CRISPR screening. <i>Nature Reviews Methods Primers</i> , 2022, 2, .	11.8	155
395	High-content CRISPR screening. <i>Nature Reviews Methods Primers</i> , 2022, 2, .	11.8	24
397	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. <i>Npj Precision Oncology</i> , 2021, 5, 103.	2.3	18
398	Immunogenomics: a potential approach for precision medicine. , 2022, , 267-277.		0

#	ARTICLE	IF	CITATIONS
399	New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. <i>Cells</i> , 2022, 11, 708.	1.8	8
400	CRISPR in cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2022, 22, 259-279.	12.8	157
401	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. <i>Nature Communications</i> , 2022, 13, 866.	5.8	51
404	Clear cell renal cell carcinoma with stage IV cavoatrial tumour thrombus extension and rapid metastatic reoccurrence postsurgical treatment with review of current treatment strategies. <i>BMJ Case Reports</i> , 2022, 15, e248156.	0.2	1
405	Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma. <i>Clinical Epigenetics</i> , 2022, 14, 42.	1.8	5
406	Evidence of antagonistic predictive effects of miRNAs in breast cancer cohorts through data-driven networks. <i>Scientific Reports</i> , 2022, 12, 5166.	1.6	0
407	The evolutionary legacy of immune checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2022, 86, 491-498.	4.3	37
409	Structures, functions, and inhibitors of LUBAC and its related diseases. <i>Journal of Leukocyte Biology</i> , 2022, 112, 799-811.	1.5	4
411	Modulation of TLR/NF- κ B/NLRP Signaling by Bioactive Phytochemicals: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834072.	1.3	13
412	Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 873116.	2.2	12
413	CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. <i>Nature Communications</i> , 2022, 13, 1606.	5.8	40
414	Tumor immunology CRISPR screening: present, past, and future. <i>Trends in Cancer</i> , 2022, 8, 210-225.	3.8	17
415	DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology. <i>SLAS Discovery</i> , 2022, 27, 121-127.	1.4	3
416	SWI/SNF Chromatin Remodeling Enzymes in Melanoma. <i>Epigenomes</i> , 2022, 6, 10.	0.8	6
417	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 98.	7.1	19
418	Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing. <i>Nature Communications</i> , 2022, 13, 1804.	5.8	26
419	Ubiquitin ligase STUB1 destabilizes IFN γ -receptor complex to suppress tumor IFN γ signaling. <i>Nature Communications</i> , 2022, 13, 1923.	5.8	18
420	Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness. <i>Nature Communications</i> , 2022, 13, 1731.	5.8	9

#	ARTICLE	IF	CITATIONS
421	Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. <i>Cell Reports</i> , 2022, 39, 110637.	2.9	12
422	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. <i>Nature Communications</i> , 2022, 13, 1898.	5.8	16
423	Central Role of the Antigen-Presentation and Interferon- β Pathways in Resistance to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2022, 6, 85-102.	2.3	15
424	Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 790967.	1.3	2
425	CD8+ T Cell-Based Molecular Classification With Heterogeneous Immunogenomic Landscapes and Clinical Significance of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 745945.	2.2	11
426	Recent Progress in the Methodologies to Identify Physiological Ligands of Siglecs. <i>Frontiers in Immunology</i> , 2021, 12, 813082.	2.2	4
427	CRISPR Screens to Identify Regulators of Tumor Immunity. <i>Annual Review of Cancer Biology</i> , 2022, 6, 103-122.	2.3	5
428	Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. <i>Cell</i> , 2022, 185, 1694-1708.e19.	13.5	100
429	Effects of HMGA2 on the epithelial-mesenchymal transition-related genes in ACHN renal cell carcinoma cells-derived xenografts in nude mice. <i>BMC Cancer</i> , 2022, 22, 421.	1.1	3
430	CAR T cell killing requires the IFN β R pathway in solid but not liquid tumours. <i>Nature</i> , 2022, 604, 563-570.	13.7	150
446	gene expression depends on BAF180 subunit of SWISNF chromatin remodeling complex and correlates with abundance of tumor infiltrating lymphocytes in ccRCC.. <i>American Journal of Cancer Research</i> , 2021, 11, 5965-5978.	1.4	0
447	The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC). , 2022, , 149-176.		5
448	Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. <i>Genome Medicine</i> , 2022, 14, 45.	3.6	73
449	Structure of human chromatin-remodelling PBAF complex bound to a nucleosome. <i>Nature</i> , 2022, 605, 166-171.	13.7	42
450	A T cell resilience model associated with response to immunotherapy in multiple tumor types. <i>Nature Medicine</i> , 2022, 28, 1421-1431.	15.2	23
451	Greek Fire, Poison Arrows, and Scorpion Bombs: How Tumor Cells Defend Against the Siege Weapons of Cytotoxic T Lymphocytes. <i>Frontiers in Immunology</i> , 2022, 13, 894306.	2.2	9
452	The roles of TGF- β 2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
453	Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
454	Role of SWI/SNF chromatin remodeling genes in lung cancer development. <i>Biochemical Society Transactions</i> , 2022, 50, 1143-1150.	1.6	6
455	Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 868480.	2.2	14
458	Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. <i>Nature Cancer</i> , 2022, 3, 734-752.	5.7	12
459	Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF- κ B activation. , 2022, 10, e004258.		8
460	PBRM1 Deficiency Sensitizes Renal Cancer Cells to DNMT Inhibitor 5-Fluoro-2â€™-Deoxycytidine. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
461	Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. <i>Life</i> , 2022, 12, 829.	1.1	8
462	Associations of DNA Methylation With Behavioral Problems, Gray Matter Volumes, and Negative Life Events Across Adolescence: Evidence From the Longitudinal IMAGEN Study. <i>Biological Psychiatry</i> , 2023, 93, 342-351.	0.7	6
463	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
464	Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. <i>Seminars in Cancer Biology</i> , 2022, 86, 477-490.	4.3	10
465	Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Gene</i> , 2022, 834, 146638.	1.0	11
466	A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in <i>NRAS</i> Mutant Melanoma. <i>Cancer Research</i> , 2022, 82, 2625-2639.	0.4	11
467	Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	1
468	Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
469	Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 306-318.	0.8	8
470	Natural killer cells in antitumour adoptive cell immunotherapy. <i>Nature Reviews Cancer</i> , 2022, 22, 557-575.	12.8	208
471	To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
472	ARID2 suppression promotes tumor progression and upregulates cytochrome 8, 18 and β -4 integrin expression in TP53-mutated tobacco-related oral cancer and has prognostic implications. <i>Cancer Gene Therapy</i> , 0, , .	2.2	5
473	PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance. <i>Genes and Development</i> , 2022, 36, 790-806.	2.7	4

#	ARTICLE	IF	CITATIONS
474	Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
475	Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing. <i>Cancer Biology and Medicine</i> , 0, , 1-18.	1.4	2
477	Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios. <i>ACS Chemical Biology</i> , 2022, 17, 2404-2410.	1.6	3
478	Cancer genes disfavoring T cell immunity identified via integrated systems approach. <i>Cell Reports</i> , 2022, 40, 111153.	2.9	4
479	Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. <i>Advanced Science</i> , 2022, 9, .	5.6	11
480	Selective suppression of melanoma lacking IFN- γ pathway by JAK inhibition depends on T cells and host TNF signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	11
482	Bourgeoning Cancer Targets. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2023, 18, 147-160.	0.8	2
483	STUB1 is an intracellular checkpoint for interferon gamma sensing. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
485	Multiple primary malignancies with complex genomic profiling. <i>Current Problems in Cancer Case Reports</i> , 2022, 7, 100185.	0.1	0
486	Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy. , 2022, 10, e004669.		7
487	PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNF α -mediated cell death. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
489	Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. <i>Nature Communications</i> , 2022, 13, .	5.8	14
490	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. <i>Nature Immunology</i> , 2022, 23, 1495-1506.	7.0	57
491	PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
492	Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	14
493	Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13714-13735.	2.9	10
494	Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12815.	1.8	4
496	Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. <i>Cancer Discovery</i> , 2023, 13, 312-331.	7.7	20

#	ARTICLE	IF	CITATIONS
497	PBRM1, SETD2 and BAP1 " the trinity of 3p in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2023, 20, 96-115.	1.9	14
498	A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. <i>Hereditas</i> , 2022, 159, .	0.5	1
499	Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	14
500	Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. <i>Cancer Cell</i> , 2022, 40, 1324-1340.e8.	7.7	11
501	Myeloid checkpoints for cancer immunotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 460-482.	0.7	7
502	SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases. <i>Cancer Cell International</i> , 2022, 22, .	1.8	7
503	ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5165-5172.	1.2	4
504	A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem. <i>Genetics & Genomics Next</i> , 2022, 3, .	0.8	3
505	SMARCA4: Current status and future perspectives in non-small-cell lung cancer. <i>Cancer Letters</i> , 2023, 554, 216022.	3.2	14
506	Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors. <i>NAR Cancer</i> , 2022, 4, .	1.6	3
507	MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. <i>Molecular Cancer Research</i> , 2023, 21, 274-289.	1.5	12
508	High-content CRISPR screening in tumor immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
509	USP2 Inhibits Lung Cancer Pathogenesis by Reducing ARID2 Protein Degradation via Ubiquitination. <i>BioMed Research International</i> , 2022, 2022, 1-15.	0.9	3
510	CRISPR screens for functional interrogation of immunity. <i>Nature Reviews Immunology</i> , 2023, 23, 363-380.	10.6	11
511	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
512	Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. <i>Cancer Research</i> , 2023, 83, 613-625.	0.4	5
513	Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
514	T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 7223.	1.0	1

#	ARTICLE	IF	CITATIONS
515	The cancer epigenome: Non-cell autonomous player in tumor immunity. <i>Cancer Science</i> , 2023, 114, 730-740.	1.7	2
516	Deregulation of SPOP in Cancer. <i>Cancer Research</i> , 2023, 83, 489-499.	0.4	10
517	A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 118.	1.8	2
518	Targeting TBK1 to overcome resistance to cancer immunotherapy. <i>Nature</i> , 2023, 615, 158-167.	13.7	30
519	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
520	Mechanism of action of the SWI/SNF family complexes. <i>Nucleus</i> , 2023, 14, .	0.6	10
521	Cancer Cell Resistance to IFN β Can Occur via Enhanced Double-Strand Break Repair Pathway Activity. <i>Cancer Immunology Research</i> , 2023, 11, 381-398.	1.6	3
522	Extracellular Vesicles and Viruses: Two Intertwined Entities. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1036.	1.8	11
523	Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. <i>Biomedicines</i> , 2023, 11, 190.	1.4	9
524	Dissecting MENIN in bivalent gene regulation. <i>Nature Cell Biology</i> , 0, , .	4.6	0
525	Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms. <i>Trends in Cancer</i> , 2023, 9, 198-211.	3.8	6
526	Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 473-490.	2.9	10
527	Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT). <i>Neuro-Oncology Practice</i> , 2023, 10, 322-334.	1.0	3
528	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
529	Base editing screens map mutations affecting interferon- β signaling in cancer. <i>Cancer Cell</i> , 2023, 41, 288-303.e6.	7.7	14
530	Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	3
531	Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4302.	1.8	0
532	Exploration of ^{68}Ga -labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. <i>Clinical Radiology</i> , 2023, 78, e417-e424.	0.5	1

#	ARTICLE	IF	CITATIONS
533	Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. <i>Nature Communications</i> , 2023, 14, .	5.8	5
534	Double-edged roles of IFN γ in tumor elimination and immune escape. <i>Journal of Pancreatology</i> , 2023, 6, 8-17.	0.3	1
535	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0
536	Discovery of Targets for Immune-Related Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha. <i>Cancer Discovery</i> , 2023, 13, 672-701.	7.7	8
540	PBRM1 bromodomains associate with RNA to facilitate chromatin association. <i>Nucleic Acids Research</i> , 2023, 51, 3631-3649.	6.5	4
541	Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. <i>Cell Reports Medicine</i> , 2023, 4, 100947.	3.3	7
542	Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines. <i>Cancer Discovery</i> , 2023, 13, 1186-1209.	7.7	1
543	Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits. <i>Medicine (United States)</i> , 2023, 102, e33059.	0.4	0
545	SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers. <i>Cancer Immunology Research</i> , 2023, 11, 646-656.	1.6	7
546	IFN γ is a central node of cancer immune equilibrium. <i>Cell Reports</i> , 2023, 42, 112219.	2.9	6
547	Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities. <i>iScience</i> , 2023, 26, 106359.	1.9	9
548	The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries. <i>Cancers</i> , 2023, 15, 1712.	1.7	3
549	Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. <i>Cancer Cell</i> , 2023, 41, 740-756.e10.	7.7	10
550	Exploring the immunological role and prognostic potential of PPM1M in pan-cancer. <i>Medicine (United States)</i> 102(10):e33059	0.4	0
551	Immunotherapy for Primary Cancers of Central Nervous System. , 2023, , 1-21.		0
552	Droplet-based forward genetic screening of astrocyte-microglia cross-talk. <i>Science</i> , 2023, 379, 1023-1030.	6.0	35
553	RNF31 promotes tumorigenesis via inhibiting RIPK1 kinase-dependent apoptosis. <i>Oncogene</i> , 0, , .	2.6	1
554	Targeting of the SWI/SNF chromatin remodeling complex in cancer therapy. <i>Uspehi Molekularnoj Onkologii</i> , 2023, 10, 8-17.	0.1	0

#	ARTICLE	IF	CITATIONS
555	ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF- κ B axis. Cell Death and Disease, 2023, 14, .	2.7	3
577	Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	30
599	Context-specific functions of chromatin remodellers in development and disease. Nature Reviews Genetics, 0, , .	7.7	3